TRAXENS/MAERSK
27.5.2019 08:32:12 CEST | Business Wire | Press release
Traxens, a company providing high-value data and services for the supply chain industry, and A.P. Moller - Maersk (“Maersk”), the integrated container logistics company, today announced that Maersk will be joining CMA CGM and MSC Mediterranean Shipping Company as a key shareholder and customer of Traxens.
Founded in 2012, Traxens has been developing unique solutions for the cargo logistics arena and has created an innovative container monitoring and coordination solution. CMA CGM first invested in the startup in 2012 and was later joined in 2016 by MSC.
A milestone in the development of Traxens
The agreement will
see Maersk invest capital in Traxens, in which it will have similar
shareholder rights as CMA CGM and MSC. Maersk also commits to order up
to 50,000 Traxens devices, a similar order to those placed earlier by
CMA CGM and MSC.
Traxens can now further focus on strengthening its solution and drive interoperability based on non-proprietary technologies and open standards. The development of Traxens as an open industry solution will benefit the strategic ambition of digitizing the container shipping industry.
Ingrid Uppelschoten Snelderwaard, Vice President, Head of Equipment, A.P. Moller - Maersk , said: “Creating visibility into the condition and location of containerized cargo is bringing Maersk’s strategy to offer digital end-to-end solutions to life. Having pioneered IoT-technology in our reefer fleet, we are excited to join Traxens and collaborate on the huge potential within connected containers. With this investment we look forward to working with key industry players to advance a leading solution within connected products and technologies for high value cargo, while ensuring customer choice through interoperability and open standards.”
Jacques Delort, General Manager of Traxens , added: “We are delighted to welcome Maersk among our backers alongside CMA CGM and MSC. Having three of the world’s largest shipping companies now supporting us, this will help accelerate our international development and contribute to our solution becoming a global market standard for the entire supply chain.”
Traxens optimizes and digitizes the supply chain
Now
counting among its customers and shareholders three of the world’s
leading shipping lines, operating nearly half the global container
fleet, Traxens offers the entire logistics ecosystem an interoperable
smart container solution. This confirms that the digitization of the
supply chain via the “smart container” is underway.
Traxens’ solution addresses key challenges in the shipping industry faced by both vessel owners and cargo owners. With the powerful combination of telematics and smart data processing, vessel owners can control costs and develop more agile business problem solving, while cargo owners can easily keep track of their containers, bringing improved business processes and decision-making capabilities.
Reduced operational costs, improved supply chain efficiency, enhanced security and the opportunity to extend offerings to customers are amongst the key benefits gained through Traxens’ smart solutions. The whole shipping ecosystem, including ports, freight forwarders, insurance and financial institutions, can also benefit from the value-added data gathered by Traxens’ cutting-edge technology.
About Traxens
Traxens generates, collects, consolidates,
enriches and transforms logistics asset data into actionable insight for
its clients in the maritime, rail and supply chain industries.
The company’s breakthrough Internet-of-Big-Things technology provides comprehensive, real-time information for managing logistics assets anywhere in the world. Traxens’ solutions digitally transform multi-modal supply chains, enabling customers to reduce costs, optimize investments, comply with environmental regulations and deliver premium services to their customers. Traxens’ IoT solution received the Frost & Sullivan’s Technology Leadership Award in 2019.
Visit Traxens at www.traxens.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20190526005023/en/
Contact:
Media Traxens Géraldine Saunière Director of communication g.sauniere@traxens.com +33 695.915.899
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom